Recursion Pharmaceuticals Inc’s recent filing unveils that its Chief Executive Officer Gibson Christopher unloaded Company’s shares for reported $0.12 million on Oct 02 ’24. In the deal valued at $6.16 per share,20,000 shares were sold. As a result of this transaction, Gibson Christopher now holds 762,656 shares worth roughly $4.71 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Gibson Christopher sold 20,000 shares, generating $121,600 in total proceeds. Upon selling the shares at $6.08, the Chief Executive Officer now owns 762,656 shares.
Before that, Borgeson Blake sold 11,447 shares. Recursion Pharmaceuticals Inc shares valued at $71,150 were divested by the Director at a price of $6.22 per share. As a result of the transaction, Borgeson Blake now holds 7,098,428 shares, worth roughly $43.87 million.
Morgan Stanley initiated its Recursion Pharmaceuticals Inc [RXRX] rating to an Equal-weight in a research note published on May 22, 2023; the price target was $8. A number of analysts have revised their coverage, including Needham’s analysts, who began to cover the stock in mid March with a ‘”a Buy”‘ rating. KeyBanc Capital Markets began covering RXRX with “an Overweight” recommendation on September 16, 2022. BofA Securities revised its rating on April 18, 2022. It rated RXRX as “a Neutral” which previously was an “a Buy”.
Price Performance Review of RXRX
On Monday, Recursion Pharmaceuticals Inc [NASDAQ:RXRX] saw its stock jump 1.15% to $6.18. Over the last five days, the stock has lost -6.22%. Recursion Pharmaceuticals Inc shares have fallen nearly -37.32% since the year began. Nevertheless, the stocks have fallen -13.08% over the past one year. While a 52-week high of $15.74 was reached on 02/27/24, a 52-week low of $4.97 was recorded on 09/04/24. SMA at 50 days reached $6.81, while 200 days put it at $8.95.
Levels Of Support And Resistance For RXRX Stock
The 24-hour chart illustrates a support level at 6.08, which if violated will result in even more drops to 5.97. On the upside, there is a resistance level at 6.24. A further resistance level may holdings at 6.29. The Relative Strength Index (RSI) on the 14-day chart is 40.48, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.48, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 89.09%. Stochastics %K at 5.83% indicates the stock is a buying.
How much short interest is there in Recursion Pharmaceuticals Inc?
A steep rise in short interest was recorded in Recursion Pharmaceuticals Inc stocks on 2024-09-13, growing by 5.02 million shares to a total of 59.16 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-15 was 54.15 million shares. There was a rise of 8.48%, which implies that there is a positive sentiment for the stock.
